No products in the cart.
Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2. ...
Tag: cabozantinib
Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed ...
#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://2minutemedicine-wpengine.netdna-ssl.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma
1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment ...
Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
Selpercatinib may provide an effective response against RET-mutated thyroid cancer
1. Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.